The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Human Pharmacokinetics of Intravenous, Sublingual, and Buccal Buprenorphine
Open accessAbstract
Buprenorphine is a potent opioid analgesic used in the treatment of moderate to severe pain. At higher doses, it has demonstrated potential for treating heroin dependence. This study was undertaken to investigate buprenorphine pharmacokinetics by different routes of administration at dosages approximating those used in opioid-dependence studies. Six healthy men who were nondependent but who had a history of heroin use were administered buprenorphine in a crossover design study by intravenous (1.2 mg), sublingual (4.0 mg), and buccal (4.0 mg) routes of administration. Plasma samples were collected up to 96 h and assayed for buprenorphine and norbuprenorphine by negative chemical ionization tandem mass spectrometry. Plasma concentrations of buprenorphine and norbuprenorphine were analyzed by nonlinear regression analysis with standard noncompartmental methods. Buprenorphine biovailability by the sublingual and buccal routes was estimated as 51.4% and 27.8%, respectively, although there was considerable interindividual variability by both routes of administration. The terminal elimination half-lives were longer for the sublingual and buccal routes than for the intravenous route. The extended elimination half-lives may be due to a shallow depot effect involving sequestration of buprenorphine in the oral mucosa. Norbuprenorphine mean peak plasma concentrations were less than 1 ng/mL and were highly variable among different routes of administration and individuals. The terminal elimination half-life of norbuprenorphine was longer than buprenorphine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jasinski, D. R. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770280111012 · Cited by 782
Clinical pharmacology of buprenorphine: Ceiling effects at high doses
Walsh, S. L., Preston, K. L., Stitzer, M. L., Cone, E. J., & Bigelow, G. E. (1994) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1994.71 · Cited by 773
Self-citationA Controlled Trial of Buprenorphine Treatment for Opioid Dependence
Johnson, R. E. (1992) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1992.03480200058024 · Cited by 572
Self-citationComparison of buprenorphine and methadone in the treatment of opioid dependence
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.7.1025 · Cited by 305
Buprenorphine suppresses heroin use by heroin addicts
Mello, N. K., & Mendelson, J. H. (1980) · Science · doi:10.1126/science.7352279 · Cited by 298
Buprenorphine versus Methadone Maintenance for Opioid Dependence
KOSTEN, T. R., SCHOTTENFELD, R., ZIEDONIS, D., & FALCIONI, J. (1993) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-199306000-00004 · Cited by 267
A clinical trial of buprenorphine: Comparison with methadone in the detoxification of heroin addicts
Bickel, W. K., Stitzer, M. L., Bigelow, G. E., Liebson, I. A., Jasinski, D. R., & Johnson, R. E. (1988) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1988.13 · Cited by 260
Self-citationFudala, P. J., Jaffe, J. H., Dax, E. M., & Johnson, R. E. (1990) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1990.67 · Cited by 191
Self-citationA placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence
Johnson, R. E., Eissenberg, T., Stitzer, M. L., Strain, E. C., Liebson, I. A., & Bigelow, G. E. (1995) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(95)01186-2 · Cited by 183
Self-citationSublingual buprenorphine used postoperatively: ten hour plasma drug concentration analysis.
Bullingham, R., McQuay, H., Porter, E., Allen, M., & Moore, R. (1982) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1982.tb01434.x · Cited by 168
Cited by
Transdermal patches: history, development and pharmacology
Pastore, M. N., Kalia, Y. N., Horstmann, M., & Roberts, M. S. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13059 · Cited by 586
Buprenorphine: Considerations for Pain Management
Johnson, R. E., Fudala, P. J., & Payne, R. (2005) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2004.07.005 · Cited by 290
Self-citationSerafini, G., Adavastro, G., Canepa, G., De Berardis, D., Valchera, A., Pompili, M., Nasrallah, H., & Amore, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082410 · Cited by 162
Treating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option
Davis, M. P., Pasternak, G., & Behm, B. (2018) · Drugs · doi:10.1007/s40265-018-0953-z · Cited by 138
Buprenorphine treatment of pregnant opioid-dependent women: maternal and neonatal outcomes
Johnson, R. E., Jones, H. E., Jasinski, D. R., Svikis, D. S., Haug, N. A., Jansson, L. M., Kissin, W. B., Alpan, G., Lantz, M. E., Cone, E. J., et al. (2001) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(00)00194-0 · Cited by 125
Self-citation
Metadata
- Authors
- Kuhlman, J. J., Lalani, S., Magluilo, J., Levine, B., Darwin, W. D., Johnson, R. E., & Cone, E. J.
- Venue
- Journal of Analytical Toxicology
- Publisher
- Oxford University Press (OUP)
- Published
- 1996-10-01
- Volume
- 20
- Issue
- 6
- Pages
- 369-378
- ISSN
- 0146-4760 (ISSN-L)
- 1945-2403
- OpenAlex
- W2053162682
- Cited by
- 273
- References
- 22
- FWCI
- 4.89
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Human Pharmacokinetics of Intravenous, Sublingual, and Buccal Buprenorphine. https://app.cochat.ai/papers/10.1093/jat/20.6.369
- The paper
- Kuhlman, J. J., Lalani, S., Magluilo, J., Levine, B., Darwin, W. D., Johnson, R. E., & Cone, E. J. (1996). Human Pharmacokinetics of Intravenous, Sublingual, and Buccal Buprenorphine. Journal of Analytical Toxicology. https://doi.org/10.1093/jat/20.6.369
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
